Press release
Leptomeningeal Metastases Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca
DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Leptomeningeal Metastases market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Leptomeningeal Metastases Market Forecast
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Leptomeningeal Metastases Market Report:
• The Leptomeningeal Metastases market size was valued at USD 1,300 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In February 2025, Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, has announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, successfully establishing a recommended Phase 2 dose (RP2D).
• In December 2024, Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system cancers, shared an update on its ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for leptomeningeal disease (LM), with a particular emphasis on breast cancer patients.
• In February 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology firm focused on oncology, announced the early conclusion of a significant two-part Phase I trial due to positive safety results and encouraging clinical responses observed thus far. This investigator-initiated study assessed the use of paxalisib, an oral dual inhibitor of PI3K/mTOR, in conjunction with radiation therapy for treating patients with brain metastases from solid tumors that have PI3K pathway mutations.
• In 2023, the United States represented around 36% of the total incident cases across various cancer types.
• In 2023, the United States reported the highest number of diagnosed cases of leptomeningeal metastases, totaling around 122,000. This figure underscores a substantial disease burden and emphasizes the need for improved diagnostic, treatment, and support strategies.
• In 2023, Japan represented about 20% of the diagnosed cases of leptomeningeal metastases.
• In 2023, Germany recorded approximately 7,800 cases of leptomeningeal metastases related to breast cancer and around 10,000 cases connected to melanoma.
• In 2023, Germany represented approximately 30% of the Leptomeningeal Metastases treatment market among the EU4 and the UK, while the UK accounted for about 20%. This share is anticipated to grow at a significant compound annual growth rate (CAGR).
• Key Leptomeningeal Metastases Companies: Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca, and others
• Key Leptomeningeal Metastases Therapies: 177Lu-DTPA-O Mburtamab Radioimmunotherapy, Rhenium-186 NanoLiposome, ANG1005, and others
• Leptomeningeal metastasis is considered the third most common metastatic complication involving the central nervous system (CNS)
Leptomeningeal Metastases Overview
Leptomeningeal metastases (LM), also known as carcinomatous meningitis, refers to the spread of malignant cells through the CSF space. These cells can originate from primary CNS tumors (e.g. drop metastases), as well as from distant tumors that have metastasized via hematogenous spread.
Get a Free sample for the Leptomeningeal Metastases Market Report:
https://www.delveinsight.com/report-store/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Leptomeningeal Metastases Epidemiology Segmentation:
The Leptomeningeal Metastases market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Leptomeningeal Metastases
• Prevalent Cases of Leptomeningeal Metastases by severity
• Gender-specific Prevalence of Leptomeningeal Metastases
• Diagnosed Cases of Episodic and Chronic Leptomeningeal Metastases
Download the report to understand which factors are driving Leptomeningeal Metastases epidemiology trends @ Leptomeningeal Metastases Epidemiological Insights
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Leptomeningeal Metastases Market Drivers
• Technological advancements
• Robust pipeline of emerging assets
• High incidence of Leptomeningeal Metastases
Leptomeningeal Metastases Therapies and Key Companies
• 177Lu-DTPA-O Mburtamab Radioimmunotherapy: Y-mAbs Therapeutics
• Rhenium-186 NanoLiposome: Plus Therapeutics
• ANG1005: AngioChem
Leptomeningeal Metastases Market Barriers
• Negative impact on quality of life
• Limited R&D
• High Leptomeningeal Metastases treatment cost
Discover more about therapies set to grab major Leptomeningeal Metastases market share @ Leptomeningeal Metastases Medications
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the Leptomeningeal Metastases Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain) and the United Kingdom, and Japan]
• Key Leptomeningeal Metastases Companies: Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca, and others
• Key Leptomeningeal Metastases Therapies: 177Lu-DTPA-O Mburtamab Radioimmunotherapy, Rhenium-186 NanoLiposome, ANG1005, and others
• Leptomeningeal Metastases Therapeutic Assessment: Leptomeningeal Metastases current marketed and Leptomeningeal Metastases emerging therapies
• Leptomeningeal Metastases Market Dynamics: Leptomeningeal Metastases market drivers and Leptomeningeal Metastases market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Leptomeningeal Metastases Unmet Needs, KOL's views, Analyst's views, Leptomeningeal Metastases Market Access and Reimbursement
To know more about Leptomeningeal Metastases treatment, visit @ Leptomeningeal Metastases Treatment Landscape
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Leptomeningeal Metastases Market Report Introduction
2. Executive Summary for Leptomeningeal Metastases
3. SWOT analysis of Leptomeningeal Metastases
4. Leptomeningeal Metastases Patient Share (%) Overview at a Glance
5. Leptomeningeal Metastases Market Overview at a Glance
6. Leptomeningeal Metastases Disease Background and Overview
7. Leptomeningeal Metastases Epidemiology and Patient Population
8. Country-Specific Patient Population of Leptomeningeal Metastases
9. Leptomeningeal Metastases Current Treatment and Medical Practices
10. Leptomeningeal Metastases Unmet Needs
11. Leptomeningeal Metastases Emerging Therapies
12. Leptomeningeal Metastases Market Outlook
13. Country-Wise Leptomeningeal Metastases Market Analysis (2020-2034)
14. Leptomeningeal Metastases Market Access and Reimbursement of Therapies
15. Leptomeningeal Metastases Market Drivers
16. Leptomeningeal Metastases Market Barriers
17. Leptomeningeal Metastases Appendix
18. Leptomeningeal Metastases Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Leptomeningeal Metastases Pipeline https://www.delveinsight.com/report-store/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Leptomeningeal Metastases Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Leptomeningeal Metastases market. A detailed picture of the Leptomeningeal Metastases pipeline landscape is provided, which includes the disease overview and Leptomeningeal Metastases treatment guidelines.
Leptomeningeal Metastases Epidemiology https://www.delveinsight.com/report-store/leptomeningeal-metastases-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Leptomeningeal Metastases Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Leptomeningeal Metastases epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leptomeningeal Metastases Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca here
News-ID: 3895253 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Leptomeningeal
Leptomeningeal Metastases Market Size, Share and Growth Report, 2034
Introduction
The Leptomeningeal Metastases (LM) market is gaining increased attention as survival rates for primary cancers improve, leading to higher detection of late-stage complications like LM. This rare but severe condition occurs when cancer cells spread to the leptomeninges and cerebrospinal fluid (CSF), most often from breast cancer, lung cancer, or melanoma. Historically associated with poor prognosis, LM treatment is evolving with advancements in molecular diagnostics, targeted therapies, intrathecal drug delivery…
Trailhead Biosystems® Develops iPSC-Derived Vascular Leptomeningeal Cells
Beachwood, Ohio, March 5, 2025 - Trailhead Biosystems, Inc. (trailbio.com), a biotechnology company pioneering the creation of iPSC-derived human cells at scale for drug discovery and cell therapy, proudly announces the launch of TrailBio® Vascular Leptomeningeal Cells. As the first of their kind on the market, these unique cells provide researchers with a new tool to directly study the blood-brain barrier's permeability and regulatory mechanisms. This advancement represents a significant…
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical …
Leptomeningeal Metastases companies are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, and others.
(Albany, USA) DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Leptomeningeal Metastases…
Leptomeningeal Metastases Treatment Market 2034: EMA, PDMA, FDA Approvals, Clini …
Leptomeningeal Metastases companies working in the market are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others.
(Albany, USA) DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United…
Leptomeningeal Metastases Treatment Market Size, Forecast, Drugs, and Companies …
Leptomeningeal Metastases Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Leptomeningeal Metastases Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Leptomeningeal Metastases, historical and…
Leptomeningeal Metastases Treatment Market Size in the 7MM was approximately USD …
Leptomeningeal Metastases Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Leptomeningeal Metastases Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Leptomeningeal Metastases, historical and forecasted…
